表紙
市場調査レポート

虚血性心疾患 (IHD) 治療薬の世界市場 (2015-2019年)

Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 336501
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
虚血性心疾患 (IHD) 治療薬の世界市場 (2015-2019年) Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019
出版日: 2015年07月29日 ページ情報: 英文 113 Pages
概要

虚血性心疾患 (IHD) は、心臓に血液を供給する動脈の収縮または閉塞を特徴とする、人間の身体における異常な状態であり、動脈内のプラーク (血小板) の蓄積に起因します。この状態は、心臓がより多くの血液の供給を要する興奮時および運動時に生じる傾向にあり、十分な血液が供給されないことによって、狭心症という反復性胸痛および不快感を伴う状態に至ります。血液の供給不足による動脈の閉塞状態が続くと心臓の組織が壊死し、心筋梗塞が引き起こされます。患者の状態に応じた治療の選択肢があり、薬物投与に関しては、スタチン、抗血小板薬、硝酸エステル、ベータ遮断薬など、多様な種類の薬物から選択することができます。Technavioのアナリストは、世界のIHD治療薬市場が2014年から2019年にかけてCAGR (複合年間成長率) 3.61%で成長すると予測しています。

当レポートでは、世界の虚血性心疾患 (IHD) 治療薬市場を取り上げ、市場の概要、市場発展促進要因、市場における課題、ならびにそれらの影響を概括し、疾患分類別・薬剤分類別・地域別に市場の現状と見通しについて調査分析するとともに、主要なベンダーの分析をまとめています。

第1章 エグゼクティブサマリー

第2章 略語集

第3章 調査範囲

  • 市場概要
  • 提供製品

第4章 市場調査手法

  • 市場調査の過程
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 疾患を理解する
  • 病因と危険因子
    • 修正可能な危険因子
    • 修正不能な危険因子
  • 病態生理学
  • 兆候と症状
  • 診断
    • ECG (心電図)
    • 負荷テスト
    • 心エコー検査
    • 胸部X線
    • 血液検査
    • 冠動脈造影法と心臓カテーテル法
  • 管理
    • 生活様式の変化
    • 薬物療法
    • 医療処置
  • 疫学
  • 経済的負担

第7章 パイプライン分析

  • パイプライン候補に関する情報
    • ONO-1101
    • Ranolazine
    • 自己移植CD34+幹細胞
    • Generx
    • Cryocell (細胞冷凍保存)
    • RVX-208
    • MPSK3169A
    • GS-6615
    • JVS-100
    • LA-419
    • ALD-201

第8章 市場情勢

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 市場区分、疾患分類別

  • 狭心症
    • 安定狭心症
    • 不安定狭心症
    • プリンツメタル狭心症
  • MI (心筋梗塞)
    • STEMI (ST上昇型心筋梗塞)
    • NSTEMI (非ST上昇型心筋梗塞)

第10章 市場区分、薬剤分類別

  • 抗脂質異常症薬
  • カルシウムチャンネル遮断薬
  • ベータ遮断薬
  • ACE (アンジオテンシン変換酵素) 阻害薬
  • ARB (アンジオテンシン受容体阻害剤)
  • 血管拡張剤
  • 抗血栓剤

第11章 地域別区分

第12章 購入条件

第13章 市場成長促進要因

第14章 促進要因とその影響

第15章 市場における課題

第16章 促進要因と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • 合併・買収
  • 市場シェア分析、2014年
    • AstraZeneca
    • Bayer
    • Eli Lilly
    • Novartis
    • Pfizer
    • Sanofi

第20章 世界のIHD治療薬市場:主な調査結果

第21章 主要ベンダーの分析 (主な情報、事業概要、事業区分別売上、地域別売上、事業戦略、最近の動向、SWOT分析)

  • AstraZeneca plc
  • Bayer
  • Eli Lilly
  • Novartis AG
  • Pfizer
  • Sanofi SA

第22章 本シリーズにおける他のレポート

図表リスト

目次
Product Code: IRTNTR6611

About IHD

IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.

Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:

  • Angina pectoris
  • Myocardial infarction.

The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • AstraZeneca
  • Bayer
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Actelion
  • Amgen
  • Baxter
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo
  • Eisai
  • F.Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Human Stem Cells Institute
  • Janssen Pharmaceuticals
  • Juventas Therapeutics
  • Lacer
  • Merck
  • Nuo Therapeutics
  • Ono Pharmaceutical
  • Pharmahungary Group
  • Resverlogix
  • Takeda Pharmaceutical Company
  • Taxus Cardium
  • The Medicines Company
  • United Therapeutics

Market Driver

  • Rise in Number of Patients
  • For a full and detailed list, view our report

Market Challenge

  • Delayed Diagnosis
  • For a full and detailed list, view our report

Market Trend

  • Increase in Health Awareness
  • For a full and detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology and Risk Factors
    • 06.2.1. Modifiable Risk Factors
    • 06.2.2. Non-modifiable Risk Factors
  • 06.3. Pathophysiology
  • 06.4. Signs and Symptoms
  • 06.5. Diagnosis
    • 06.5.1. ECG
    • 06.5.2. Stress Testing
    • 06.5.3. Echocardiography
    • 06.5.4. Chest X-Ray
    • 06.5.5. Blood Tests
    • 06.5.6. Coronary Angiography and Cardiac Catheterization
  • 06.6. Management
    • 06.6.1. Lifestyle Changes
    • 06.6.2. Pharmacotherapy
    • 06.6.3. Medical Procedures
  • 06.7. Epidemiology
  • 06.8. Economic Burden

07. Pipeline Analysis

  • 07.1. Information on Pipeline Candidates
    • 07.1.1. ONO-1101
    • 07.1.2. Ranolazine
    • 07.1.3. Autologous CD34+ stem cells
    • 07.1.4. Generx
    • 07.1.5. Cryocell
    • 07.1.6. RVX-208
    • 07.1.7. MPSK3169A
    • 07.1.8. GS-6615
    • 07.1.9. JVS-100
    • 07.1.10. LA-419
    • 07.1.11. ALD-201

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Disease Class

  • 09.1. Angina Pectoris
    • 09.1.1. Stable Angina
    • 09.1.2. Unstable Angina
    • 09.1.3. Prinzmetal's Angina
  • 09.2. MI
    • 09.2.1. STEMI
    • 09.2.2. NSTEMI

10. Market Segmentation by Drug Class

  • 10.1. Anti-dyslipidemic Drugs
  • 10.2. Calcium Channel Blockers
  • 10.3. Beta-blockers
  • 10.4. ACE Inhibitors
  • 10.5. ARBs
  • 10.6. Vasodilators
  • 10.7. Antithrombotic Agents

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. AstraZeneca
    • 19.2.2. Bayer
    • 19.2.3. Eli Lilly
    • 19.2.4. Novartis
    • 19.2.5. Pfizer
    • 19.2.6. Sanofi
  • 19.3. Other and Future Prominent Vendors

20. Global IHD Drugs Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. AstraZeneca plc
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Business Segmentation by Revenue 2011-2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Bayer
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Business segmentation by revenue 2014
    • 21.2.4. Business segmentation by revenue 2013 and 2014
    • 21.2.5. Geographical segmentation by revenue 2014
    • 21.2.6. Business strategy
    • 21.2.7. Recent developments
    • 21.2.8. SWOT analysis
  • 21.3. Eli Lilly
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue
    • 21.3.4. Sales by Geography
    • 21.3.5. Business Strategy
    • 21.3.6. Key Information
    • 21.3.7. SWOT Analysis
  • 21.4. Novartis AG
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. Pfizer
    • 21.5.1. Key facts
    • 21.5.2. Business overview
    • 21.5.3. Business segmentation by revenue 2014
    • 21.5.4. Business segmentation by revenue 2013 and 2014
    • 21.5.5. Geographical segmentation by revenue 2014
    • 21.5.6. Business strategy
    • 21.5.7. Key developments
    • 21.5.8. SWOT analysis
  • 21.6. Sanofi SA
    • 21.6.1. Key Facts
    • 21.6.2. Business Description
    • 21.6.3. Business Segmentation
    • 21.6.4. Revenue by Business Segmentation
    • 21.6.5. Revenue Comparison 2012 and 2013
    • 21.6.6. Sales by Geography
    • 21.6.7. Business Strategy
    • 21.6.8. Key Developments
    • 21.6.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Overview of IHD
  • Exhibit 3: Pathophysiology of IHD
  • Exhibit 4: Leading Cause of Death in World 2012
  • Exhibit 5: Leading Cause of Death in US 2013
  • Exhibit 6: Pipeline Portfolio of IHD Drugs
  • Exhibit 7: Global IHD Drugs Market 2014-2019 ($ millions)
  • Exhibit 8: Global IHD Drugs Market Segment by Disease Class
  • Exhibit 9: Global IHD Drugs Market Segment by Drug Class
  • Exhibit 10: Segmentation of Global IHD Drugs Market by Geography 2014
  • Exhibit 11: YoY Growth and Revenue of Atacand 2010-2014 ($ millions)
  • Exhibit 12: YoY Growth and Revenue of Crestor 2010-2014 ($ millions)
  • Exhibit 13: YoY Growth and Revenue of Seloken/Toprol-XL 2010-2014 ($ millions)
  • Exhibit 14: YoY Growth and Revenue of Adalat 2010-2014 ($ millions)
  • Exhibit 15: YoY Growth and Revenue of Xarelto 2010-2014 ($ millions)
  • Exhibit 16: YoY Growth and Revenue of Effient 2010-2014 ($ millions)
  • Exhibit 17: YoY Growth and Revenue of Diovan 2010-2014 ($ millions)
  • Exhibit 18: YoY Growth and Revenue of Exforge 2010-2014 ($ millions)
  • Exhibit 19: YoY Growth and Revenue of Caduet 2010-2014 ($ millions)
  • Exhibit 20: YoY Growth and Revenue of Fragmin 2010-2014 ($ millions)
  • Exhibit 21: YoY Growth and Revenue of Lipitor 2010-2014 ($ millions)
  • Exhibit 22: YoY Growth and Revenue of Norvasc 2010-2014 ($ millions)
  • Exhibit 23: YoY Growth and Revenue of Lovenox 2010-2014 ($ millions)
  • Exhibit 24: YoY Growth and Revenue of Plavix 2010-2014 ($ millions)
  • Exhibit 25: Global IHD Drugs Market: Key Takeaways
  • Exhibit 26: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 ($ millions)
  • Exhibit 28: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 29: Bayer: Business segmentation by revenue 2014
  • Exhibit 30: Bayer: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 31: Bayer: Geographical segmentation by revenue 2014
  • Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 34: Eli Lilly: Sales by Geography 2013
  • Exhibit 35: Novartis AG: Business Segmentation
  • Exhibit 36: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 37: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 38: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 39: Pfizer: Business segmentation by revenue 2014
  • Exhibit 40: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 41: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 42: Sanofi SA: Business Segmentation
  • Exhibit 43: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 44: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 45: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top